The week in health tech, explained in plain English.Get the free newsletter →
October 25, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Hospitals

U of Iowa Health Care Scraps $2B Patient Tower Plan

University of Iowa Health Care is walking away from a more than $2 billion inpatient tower, choosing to renovate and expand its current footprint instead. The Iowa City-based academic health system announced the change in a Sept. 9 statement, ahead of an Iowa Board of Regents meeting scheduled later this month, according to Becker's Hospital Review.

The reversal reflects a broader recalibration among hospitals weighing massive new construction against tighter margins, high borrowing costs, and rising building expenses. Renovating and adding to existing buildings can deliver more beds and updated space faster and at lower cost than a ground-up tower, though it comes with its own constraints on layout and capacity.

For a state's flagship academic medical center, the decision signals caution about locking in a decade-long capital commitment. Readers should watch the Board of Regents meeting for details on what the modernization plan will cost, how many beds it adds, and the timeline, which will show whether the scaled-back approach actually meets patient demand.

More in Hospitals

Hospitals

Visitor Fatally Shot at HCA Missouri Hospital; Patient Charged

A visitor was fatally shot at HCA Healthcare's Centerpoint Medical Center in Missouri, and patient James Lawson faces second-degree murder charges.

Why it matters: Violence inside hospitals is driving systems to rethink weapons screening and access control to protect patients, staff, and visitors.

Hospitals

Pay Dispute Puts Illinois Hospital's Trauma Status at Risk

An Illinois hospital's level 2 trauma designation is under state review after its anesthesia group suspended services over a missed payment.

Why it matters: A single vendor contract breakdown can strip a hospital of its trauma status and leave a community without nearby emergency surgical care.

Hospitals

Merck-Moderna mRNA Cancer Vaccine Cuts Melanoma Risk 42%

Merck and Moderna's personalized mRNA cancer vaccine cut melanoma recurrence or death by 42% in a phase 3 trial when paired with Keytruda immunotherapy.

Why it matters: A successful phase 3 readout signals that personalized mRNA cancer vaccines are nearing clinical reality for high-risk cancer patients.